[Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect]
- PMID: 35925327
- DOI: 10.1007/s00347-022-01660-0
[Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect]
Similar articles
-
[Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin].J Fr Ophtalmol. 2021 May;44(5):766-768. doi: 10.1016/j.jfo.2020.07.008. Epub 2021 Jan 14. J Fr Ophtalmol. 2021. PMID: 33454122 French. No abstract available.
-
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23. Oncologist. 2021. PMID: 33179377 Free PMC article. Clinical Trial.
-
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.Drug Des Devel Ther. 2021 Jun 2;15:2401-2415. doi: 10.2147/DDDT.S267404. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34103900 Free PMC article. Review.
-
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.Clin Pharmacol Ther. 2021 Nov;110(5):1282-1292. doi: 10.1002/cpt.2409. Epub 2021 Oct 4. Clin Pharmacol Ther. 2021. PMID: 34468979 Free PMC article. Clinical Trial.
-
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.Future Oncol. 2020 Dec;16(34):2783-2798. doi: 10.2217/fon-2020-0521. Epub 2020 Sep 2. Future Oncol. 2020. PMID: 32875817 Review.
Cited by
-
[Corneal events with mirvetuximab soravtansine : A review of ocular surface events associated with the tubulin-acting antibody-drug conjugate, mirvetuximab soravtansine].Ophthalmologie. 2025 Sep 2. doi: 10.1007/s00347-025-02306-7. Online ahead of print. Ophthalmologie. 2025. PMID: 40892244 Review. German.
References
Literatur
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical